Literature DB >> 29383698

Infusion-fill method versus standard auto-fill trial of void protocol following a TVT-exact procedure: A randomised controlled trial.

Alexandra Mowat1, Bernadette Brown2, Anita Pelecanos3, Victoria Mowat4, Malcolm Frazer5.   

Abstract

OBJECTIVE: To establish whether the infusion method trial of void (TOV) after a mid-urethral sling procedure, in contrast to the standard auto-fill TOV, permits discharge home from recovery, as these procedures are eminently suited to same day discharge, and the delay in achieving a successful TOV often keeps the patient in hospital overnight.
METHOD: A randomised controlled trial performed between December 2014 and April 2016 at the University Hospital, enrolling 40 women undergoing a mid-urethral sling procedure for stress urinary incontinence. The women were randomised to infusion method or auto-fill method TOV. The primary outcome was discharge home from the recovery area of theatre.
RESULTS: Discharge from recovery was not different between the two groups (odds ratio (OR) 1.3 95% CI: 0.3-5.9, P = 0.71). The rate of TOV being successfully passed in recovery was higher in the infusion-fill group compared to the standard auto-fill group (OR 4.5 95% CI 1.2-17.4, P = 0.025). This means that three women will undergo the infusion-fill to achieve one more successful TOV in recovery.
CONCLUSIONS: The infusion method resulted in more women passing their TOV in recovery but this did not translate into more discharges from recovery.
© 2018 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  mid-urethral sling; trial of void

Mesh:

Substances:

Year:  2018        PMID: 29383698     DOI: 10.1111/ajo.12780

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  1 in total

1.  Comment: quicker trial of void after midurethral sling procedure many not lead to earlier discharge times.

Authors:  Alexandra Mowat; Malcolm Frazer
Journal:  Int Urogynecol J       Date:  2018-03-19       Impact factor: 2.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.